Replies to post #161308 on Biotech Values

[mcbio]

UPDATE: Esperion Therapeutics wants to go public too. This week the Plymouth, MI-based drug developer filed for a maiden public offering to raise up to $70 million. The company comes to the table with a cholesterol-lowering drug called ETC-1002, which has completed early midstage trials. This is the new Esperion. Pfizer acquired the old Esperion in 2004. Afterward, entrepreneurs formed Esperion and grabbed rights to ETC-1002 from Pfizer, which had acquired the compound in the buyout of the original Esperion.

The obvious question to me is what has Esperion done to solve the manufacturing (and other) issues that plagued their drug after PFE acquired the company originally (#msg-81663057 ) ?